Senseonics Holdings (SENS) Stock Overview
A commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SENS Community Fair Values
Create NarrativeSee what 27 others think this stock is worth. Follow their fair value or set your own to get alerts.
Senseonics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.48 |
| 52 Week High | US$1.40 |
| 52 Week Low | US$0.25 |
| Beta | 0.99 |
| 1 Month Change | -9.00% |
| 3 Month Change | -28.35% |
| 1 Year Change | 20.36% |
| 3 Year Change | -53.29% |
| 5 Year Change | 24.55% |
| Change since IPO | -85.34% |
Recent News & Updates
Shareholder Returns
| SENS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -4.0% | 3.3% | 2.9% |
| 1Y | 20.4% | 12.1% | 13.9% |
Return vs Industry: SENS exceeded the US Medical Equipment industry which returned 9.6% over the past year.
Return vs Market: SENS exceeded the US Market which returned 13.7% over the past year.
Price Volatility
| SENS volatility | |
|---|---|
| SENS Average Weekly Movement | 10.5% |
| Medical Equipment Industry Average Movement | 8.9% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: SENS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SENS's weekly volatility has decreased from 17% to 11% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 117 | Tim Goodnow | www.senseonics.com |
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company’s products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners.
Senseonics Holdings, Inc. Fundamentals Summary
| SENS fundamental statistics | |
|---|---|
| Market cap | US$399.68m |
| Earnings (TTM) | -US$74.00m |
| Revenue (TTM) | US$23.68m |
Is SENS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SENS income statement (TTM) | |
|---|---|
| Revenue | US$23.68m |
| Cost of Revenue | US$21.98m |
| Gross Profit | US$1.70m |
| Other Expenses | US$75.70m |
| Earnings | -US$74.00m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.091 |
| Gross Margin | 7.19% |
| Net Profit Margin | -312.47% |
| Debt/Equity Ratio | 99.3% |
How did SENS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/30 07:58 |
| End of Day Share Price | 2025/06/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Senseonics Holdings, Inc. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Chodaczek | B. Riley Securities, Inc. |
| Marie Thibault | BTIG |
| Michael Gorman | BTIG |